Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > LX-4211

LX-4211

pharmaceutical raw materials
LX-4211 structure

LX-4211 

structure
  • CAS No:

    1018899-04-1

  • Formula:

    C21H25ClO5S

  • Chemical Name:

    LX-4211

  • Synonyms:

    (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(methylsulfanyl)tetrahydro-2-H-pyran-3,4,5-triol;CS-1853;LX4211; LX 4211; LX4211; LX 4211;LX-4211;(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(Methylthio)tetrahydro-2H-pyran-3,4,5-triol;(5S)-Methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-1-thio-beta-L-xylopyranoside;LX4211/LX-4211;LP 802034

  • Categories:

    Biochemical Engineering  >  Saccharides

Description

Sotagliflozin has been used in trials studying the treatment of Renal impairment, Hepatic Impairment, Type 1 Diabetes Mellitus, and High Level of Sugar (Glucose) in the Blood.|Sotagliflozin is an orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity. Upon oral administration, sotagliflozin binds to and blocks both SGLT1 in the gastrointestinal (GI) tract and SGLT2 in the kidneys, thereby suppressing the absorption of glucose from the GI tract and the reabsorption of glucose by the proximal tubule into the bloodstream, respectively. This decreases glucose uptake and enhances the urinary excretion of glucose, which lowers and/or normalizes blood glucose levels. SGLT1 is the primary transporter responsible for glucose absorption from the GI tract. SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid.

LX-4211 Basic Attributes

424.94

424.94

6B4ZBS263Y

DTXSID20144314

C119623

White to off-white

A10|A - Alimentary tract and metabolism

Characteristics

1.37±0.1 g/cm3(Predicted)

607.9±55.0 °C(Predicted)

12.87±0.70(Predicted)

Store at -20°C

Safety Information

|Warning|H351 (50%): Suspected of causing cancer [Warning Carcinogenicity]|P201, P202, P260, P273, P281, P308+P313, P314, P405, and P501|Aggregated GHS information provided by 3 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Drug Information

Zynquista is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.|Treatment of type I diabetes mellitus|Treatment of type II diabetes mellitus

Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney, and are used in the treatment of TYPE 2 DIABETES MELLITUS. (See all compounds classified as Sodium-Glucose Transporter 2 Inhibitors.)

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol

LX-4211 Use and Manufacturing

Uses

Sotagliflozin is used for the treatment of patients with type 1 diabetes mellitus.

Human drugs -> Zynquista -> EMA Drug Category|Drugs used in diabetes -> Human pharmacotherapeutic group|Human Drugs -> EU pediatric investigation plans

Recommended Suppliers of LX-4211

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.